摘要
目的探讨依达拉奉对急性大面积脑梗死患者高敏C反应蛋白的影响。方法选择本院2006年12月至2008年12月急性大面积脑梗死患者86例，随机分为两组，治疗组和对照组。对照组采用常规治疗，治疗组在对照组基础上给予依达拉奉治疗。14d为一个疗程。在治疗前、治疗后检查两组患者血清高敏C反应蛋白水平。在两个疗程结束后，比较两组的治疗效果。结果①两组总有效率比较，差异有统计学意义（P〈0．05）；②两组治疗第7、14天高敏C反应蛋白水平，与治疗前比较，差异有统计学意义（P〈0．01）；治疗组治疗第7、14天高敏C反应蛋白水平分别与对照组同期相比，差异有统计学意义（P〈0．05）。结论依达拉奉能够显著降低急性脑梗死患者血清高敏C反应蛋白水平，临床治疗效果显著，值得临床借鉴。
Objective To explore the effects of edaravone on high sensitivity C-reaction protein （hsCRP） in patients with acute massive cerebral infarction. Methods 86 cases with acute massive cerebral infarction were selected from December 2006 to December 2008. all the cases were divided into two groups, control group and cure group, routine treatment was used to the control group, on the basis of control group＇ therapy, edaravone was given to cure group, the level of hsCRP was detected before and after treatment, and the results of cure was compared. Results （1）the total effective rate in two groups existed statistical difference （ P 〈 0.05 ） ; （2） the level of hsCRP in two groups before treatment and in the 7th and the 14th of treatment existed statistical difference （P 〈 0. 01 ）, the level of hsCRP in the 7th and the 14th of treatment in cure group existed statistical difference （P 〈 0. 05）. Conclusion Edaravone can decrease the level of hsCRP in patients with massive cerebral infarction, and has significant clinical efficacy, which should be the reference for the doctors.
出处
《中国临床实用医学》
2010年第4期110-112,共3页
China Clinical Practical Medicine
关键词
大面积脑梗死
依达拉奉
C反应蛋白
Massive cerebral infarction
Edaravone
C-reaction protein
